| Company | Introduction |
| Trevi Therapeutics | Trevi is developing the investigational oral therapy Haduvio™ (nalbuphine ER) to treat chronic cough associated with idiopathic pulmonary fibrosis (IPF) and pruritus due to prurigo nodularis (PN). |
| 标的公司是一家美国制药公司，总部位于美国纽黑文。该公司正在开发口服纳布啡缓释剂，通过靶向中枢和外周神经系统来治疗严重的神经介导病症。 | |
| Innova Therapeutics | Innova Therapeutics is a Charleston, South Carolina-based biotechnology company developing a monoclonal antibody (mAb) platform that targets a highly expressed protein in various solid cancers and has shown to correlate with patient outcomes. The lead humanized mAb has been selected and designated as IVT-8086. Innova’s initial platform technology is focused on targeting cancers, including pediatric osteosarcoma, sarcomas, triple-negative breast cancer, and pancreatic cancer, but has broad benefit across most solid and hematological tumors. The focus on pediatric osteosarcoma will allow fast-regulatory approval. Osteosarcoma is a rare disease that was granted both orphan designation and rare pediatric disease designation from the FDA. This will expedite the regulatory approval timeline, including the opportunity to obtain a Rare Pediatric Disease priority review voucher. Because Priority Review Vouchers (PRVs) may be sold, a secondary market for the vouchers has emerged with revenue ranging between $80M and $350M. |
| Innova是一家总部位于南卡罗来纳州查尔斯顿的生物技术公司。该公司开发的单克隆抗体平台是靶向一种在多种实体癌中高表达且与患者预后相关的蛋白质。 标的公司是在联合创始人 Nancy Klauber DeMore 和 Cam Patterson 的研究基础上成立的，由联合创始人兼首席执行官 Robert Ryan 领导。该团队曾是生物技术公司 Sciderm 的管理团队。 | |
| ENYO | ENYO Pharma is a privately held, clinical stage biopharmaceutical company incorporated in January 2014 and headquartered in Lyon, France. The Company’s most advanced compound, EYP001, is a small molecule (non-Bile Acid FXR agonist) therapeutic in Phase II clinical development for the treatment of Chronic Hepatitis B and NASH. EYP001 and the Company’s discovery programs are based on a proprietary technology platform that uses a virus bio-mimetism approach to enable the rapid discovery of first-inclass drug candidates with good safety profiles. ENYO’s founders are a mix of virus-host protein interactions experts from the French Infectiology Research Center in Lyon and pharmaceutical industry executives with an impressive track record in drug development. |
| ENYO成立于2014年1月，总部设在法国里昂，并在澳大利亚墨尔本设有子公司。其创始团队是来自法国里昂国际传染病研究中心（International Center for Research in Infectiology）病毒—宿主蛋白相互作用领域的专家，以及医药行业专注于新药开发的高管。ENYO正在研发的主打产品为EYP001，有望治愈慢性乙型肝炎（HBV）。 该公司最大特点是通过模仿病毒复制策略调节宿主细胞功能，来开发创新候选药物。ENYO已经开创了全新的方法，并建立了独特的药物发现引擎，该引擎模拟一种策略——即病毒如何在进化过程中为自身的生存和自我保护而阻止人类宿主细胞的功能。ENYO还开发出了包含所有已知病毒/人类蛋白-蛋白相互作用的数据库，并从这些相互作用中发现新的目标。 | |
| Rednvia | REDNVIA is a clinical-stage pharmaceutical company focusing on transformative therapies for cardiovascular diseases, especially developing the RNV-1001 program (DA-1229/Evogliptin) as a treatment for CAVD (Calcific Aortic Valve Disease) that doesn’t have any approved therapy so far. |
| Rednvia成立于2018年，是一家总部位于韩国，并在美国建立了分部的临床阶段生物医药公司。公司专注于小分子和心脑血管疾病的药物研发。公司于2018年引进了韩国东亚公司研发的依格列汀（Evogliptin）专利并开展了针对主动脉瓣钙化疾病适应症的临床试验。依格列汀是一种DPP-4抑制剂，用于治疗II型糖尿病。由韩国东亚公司研发，于2015年10月2日获得韩国食品药品安全部批准上市，商品名为：Sugarnon®。公司从东亚公司获得了该产品用于主动脉瓣钙化疾病适应症的开发和商业化的独家许可权。 | |
| Regeneus | Regeneus is a publicly traded (ASX: RGS), clinical stage, regenerative medicine company poised to address unmet clinical needs in osteoarthritis, neuropathic pain and wound healing. Regeneus’ novel technology platform leverages the potential of adipose-derived mesenchymal signaling cells (MSCs) and associated secretome to stimulate tissue healing and modulate pain. Target clinical indications for the company’s two product candidates (Progenza™, Sygenus™) collectively represent $10B+ of addressable market opportunity in the U.S. alone. |
| Regeneus成立于2007年，是一家位于澳大利亚的临床阶段的再生医学公司，公司市值约1400万美金。该公司拥有独特的细胞治疗技术平台，致力于利用干细胞技术解决骨关节炎、神经性疼痛和伤口愈合方面未满足的临床需求。标的资产已和日本Kyocera公司于2021年签订产品在日本的授权合作协议，现在中国寻求产品授权合作伙伴。 | |
| Antabio | Antabio is a privately held biopharmaceutical company that develops novel antimicrobial resistance disruptors for the treatment of drug-resistant infections |
| Antabio是一家私营生物制药公司，开发新型抗菌抗性破坏剂，用于治疗耐药性感染 | |
| Inorbit Therapeutics AB | Inorbit is a drug discovery company aiming to resurrect drugs with proven human efficacy, but which failed due to Drug-Induced liver Injury, by applying its novel unique chemistry platform. Inorbit is currently focused on target markets like the fatty liver diseases NAFLD and NASH. The company has a virtual nature, relying on an excellent network of collaborators. In this way, Inorbit performs efficient and cost-effective drug discovery. |
| Inorbit是一家药物开发公司，旨在利用其独特的化学平台，使已证明对人体有效的药物复活，但因药物诱导肝损伤而失败。Inorbit目前专注于目标市场，如脂肪肝疾病NAFLD和NASH。公司具有虚拟性质，依托优秀的合作网络。通过这种方式，Inorbit能够高效、经济地进行药物研发 | |
| Scandion Oncology A/S | Scandion Oncology discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. |
| Scandion Oncology致力于开发FIC（First In Class）创新药物，专注于治疗对当前治疗方案具有耐药性的癌症。 | |
| Synsight | SYNSIGHT is specialized in drug discovery, especially in small molecules drugs targeting RNA. Its innovative drug discovery platform is at the convergence of artificial intelligence and cellular imaging. SYNSIGHT develops a portfolio of proprietary and partnered therapeutic projects. |
| SYNSIGHT是一家专门从事治疗分子的发现和开发，特别是针对蛋白质- rna相互作用的公司。由于其发现平台，人工智能和细胞成像的融合，SYNSIGHT开发了一系列专利和合作治疗项目。 | |
| AlgoTherapeutix | At AlgoTx aim at developing novel solutions to relieve patients with difficult-to-treat . They do so by repurposing existing drugs towards topical pain relief, where no existing therapy provides a convincing balance of efficacy and adverse events. |
| AlgoTx旨在开发新的解决方案，以缓解难以治疗的“复杂疼痛”患者。他们通过将现有的药物重新用于局部疼痛缓解，而现有的治疗方法无法提供令人信服的疗效和不良事件的平衡。 | |
| Nanokide Therapeutics | Nanokide Therapeutics is a biotechnology company focused on the development of novel antimetastatic solutions based on the combination of nanotechnology and microRNA and mRNA. The nanosystems is a flexible, non-toxic and easy to produce formulation that combined with microRNA and mRNA sequences offer a perfect platform for anticancer drugs development. |
| Nanokide Therapeutics是一家生物技术公司，专注于开发基于纳米技术、microRNA和mRNA结合的新型抗转移解决方案。 纳米系统是一种灵活、无毒、易于生产的配方，结合microRNA和mRNA序列，为抗癌药物的开发提供了一个完美的平台。 | |
| Optosolve | The asset has the potential to be the first-in-class topical analgesic for post-ophthalmic surgical pain, currently there is no approved topical ophthalmic analgesics in China; – Topical re-formulation of classic analgesic tramadol exploits its unique multi-modal corneal action with minimal systemic exposure – Gel formulation delivers near immediate action with increased corneal residency time avoiding CNS or potential addictive risk; – Lower dosage improving safety profile, four days’ dosage equivalent to about only one tra-madol 50mg tablet; Mechanism：Tramadol is a narcotic-like pain reliever used to treat moderate to severe pain in adults. Topical formulation exploits tramadol’s unique peripheral action to provide rapid effective corneal analgesia, while avoiding unwanted CNS narcotic effects, creating a near ideal topical anal-gesic. Stage: Pre-IND consultation with US-FDA completed, and phase II dose optimization and con-firmatory trial planned for late 2021. |
| 公司开发了一款first-in-class 曲马多滴眼液用于眼科术后镇痛。用于治疗成人中度至重度疼痛。该曲马多外用制剂可利用其独特的外周作用来提供快速有效的角膜镇痛，同时避免不良的中枢神经系统麻醉作用，起到近乎理想的局部镇痛效果。 已完成在研究者发起的临床试验(investigator initiated trial,IIT)，与美国FDA 开过 Pre-IND 会议，并计划下一步进行剂量优化和验证性试验的 II 期临床。 | |
| Lytix Biopharma | Established in 2003, Lytix Biopharma, is a clinical-stage biotech company located in Norway. It is listed on Oslo Stock Exchange with a market cap of nearly $60 million Lytix develops novel cancer immunotherapies through its pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. The company’s management team and advisory board members have a profund experience in oncology/immunology including James Allison who won the Nobel Prize for the discovery of immune checkpoint inhibitors. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic peptide with the potential to personalize immunotherapy. Their portfolio also includes a follow-on first-in-class oncolytic small molecule,LTX-401, in final pre-clinical stage, aimed to be developed towards liver cancer, in particular hepatocellular carcinoma. |
| 标的公司成立于 2003 年， 是一家致力于利用“宿主防御肽”（对抗外来病原体的第一道天然防线）技术开发新型癌症免疫疗法的临床阶段生物公司，总部位于挪威。 公司在 2021 年 Pre-IPO 轮中融资近 3000 万美元， 随后在奥斯陆证券交易所上市。标的公司的管理团队在肿瘤学和免疫学方面有着丰富的经验，其中包括诺贝尔奖获得者 James P. Allison。 | |
| EpiAxis Therapeutics | EpiAxis Therapeutics Pty Ltd (“EpiAxis”) is a privately funded, epigenetically focused translational drug discovery Company developing novel cancer therapeutics. The Company was established in 2015 and is developing nuclear translocation inhibitors against lysine-specific demethylase 1 (“LSD1”), directed against cancer progression and metastasis. EpiAxis’ key point of differentiation is the way that it targets dormant cancer cells and epigenetically re-programs them back to a normal cell phenotype, decreasing their resistance to therapies, and reinvigorating the immune system. |
| Oryzon Genomics,S.A. | ORYZON is a public clinical stage biopharmaceutical company developing innovative epigenetic personalized medicines for patients with cancer and CNS disorders |
| ORYZON是一家处于公共临床阶段的生物制药公司，为癌症和中枢神经系统疾病患者开发创新的表观遗传个性化药物 |
April 18 | Spring showcase 2022
BioToChina.org 